Long non-coding RNA ATB promotes malignancy of esophageal squamous cell carcinoma by regulating miR-200b/Kindlin-2 axis

Zhongwen Li1,8, Xiaoliang Wu2,3,8, Ling Gu2,3,4,8, Qi Shen2, Wen Luo2, Chuangzhong Deng2, Qianghua Zhou3, Xinru Chen4, Yanjie Li3, ZuanFu Lim6, Xing Wang3, Jiahong Wang*3,7 and Xianzi Yang*3,7

Esophageal squamous cell carcinoma (ESCC) is one of the leading causes of cancer-related death, especially in China. In addition, the prognosis of late stage patients is extremely poor. However, the biological significance of the long non-coding RNA Inc-ATB and its potential role in ESCC remain to be documented. In this study, we investigated the role of Inc-ATB and the underlying mechanism promoting its oncogenic activity in ESCC. Expression of Inc-ATB was higher in ESCC tissues and cell lines than that in normal counterparts. Upregulated Inc-ATB served as an independent prognosis predictor of ESCC patients. Moreover, loss-of-function assays in ESCC cells showed that knockdown of Inc-ATB inhibited cell proliferation and migration both in vitro and in vivo. Mechanistic investigation indicated that Inc-ATB exerted oncogenic activities via regulating Kindlin-2, as the anti-migration role of Inc-ATB silence was attenuated by ectopic expression of Kindlin-2. Further analysis showed that Inc-ATB functions as a molecular sponge for miR-200b and Kindlin-2. Dysregulated miR-200b/Kindlin-2 signaling mediated the oncogenic activity of Inc-ATB in ESCC. Our results suggest that Inc-ATB predicts poor prognosis and may serve as a potential therapeutic target for ESCC patients.

Cell Death and Disease (2017) 8, e2888; doi:10.1038/cddis.2017.245; published online 22 June 2017

Esophageal cancer has the eighth highest incidence rate among all cancer types worldwide, with varying occurrences from country to country.1,2 China is one of those countries with highest risk of esophageal cancer.3 Esophageal squamous cell carcinoma (ESCC) arising from the squamous epithelium accounts for the most prevalent histological subtype.2 Despite recent advances in diagnosis technologies such as endoscopic ultrasonography and wide application of chemoradiotherapy combined with esophagectomy surgery in ESCC,4,5 the overall survival of stage III patients is approximately 10–15% and <12 months for late stage patients.5 Therefore, new molecular biomarkers associated with tumor development and prognosis prediction are urgently needed in order to improve the understanding and outcome of this lethal disease.

Cancer is fundamentally regarded as a genetic disease5 that alters cellular information flow leading to uncontrolled proliferation and re-balanced cellular homeostasis.8,9 Recent multiple genome-wide cancer studies have revealed an extensive landscape of long non-coding RNAs (lncRNAs) with exquisite regulation of the malignant transformation via interaction with other cellular macromolecules.8,9 LncRNAs are a group of transcripts longer than 200 nucleotides from non-protein coding regions of the genome, the number of which is estimated to outnumber that of the protein coding genes.11 It is now recognized that IncRNAs may act as molecular sponge and competitively suppress expression of microRNAs (miRNAs).10,11 One such IncRNA is the lncRNA activated by transforming growth factor β (TGF-β) (Inc-ATB), which was located in human chromosome 14 with 2446 nucleotides in length (Supplementary Table 1). Lnc-ATB contains multiple miR-200-binding sites and is known to be the mediator for TGF-β-induced epithelial–mesenchymal transition (EMT) in hepatocellular carcinoma.12 Moreover, Inc-ATB could promote trastuzumab resistance and the invasion-metastasis cascade in breast cancer by competitively binding miR-200c and upregulating ZEB1 and ZNF-217, resulting in EMT.13 Dysregulation of Inc-ATB have been reported in human tumors including gastric,14 colorectal,15,16 brain,17 pancreatic18 and renal19 cancer. However, expression of Inc-ATB in ESCC and the underlying mechanisms remain unsolved.

Results

Lnc-ATB is upregulated in ESCC cancer tissues and cell lines and predicts unfavorable prognosis of ESCC patients. To define the role of Inc-ATB in ESCC, we examined the expression level of Lnc-ATB in 150 paired ESCC cancer and normal squamous epithelial tissues by
qRT-PCR. We found that lnc-ATB was significantly upregulated in ESCC cancer tissues compared with the matched adjacent normal tissues (Figure 1a). Furthermore, expression of lnc-ATB was also determined in a panel of ESCC cancer cell lines (KYSE30, Eca109, Eca9706, KYSE510, KYSE520, KYSE410, KYSE140 and KYSE150) and the normal epithelial cell line NE1. The results showed that lnc-ATB expression was upregulated in the ESCC cancer cell lines when compared with NE1 cells (Figure 1b).

We then analyzed the correlation between Lnc-ATB expression and the clinicopathological features of 150 ESCC patients. Using the median expression level as the cutoff value, our patient cohort was assigned into high Lnc-ATB expression group (above the median, \( n = 75 \)) and low Lnc-ATB expression group (below the median, \( n = 75 \)) (Figure 1c). The correlations between expression of Lnc-ATB and the clinical pathological parameters of ESCC patients are summarized in Table 1.

To further analyze whether Lnc-ATB expression could be a potential prognosis predictor in ESCC patients, we performed a Kaplan–Meier analysis with log-rank test. The results showed that the median overall survival of patients with high Lnc-ATB expression was 20 months, whereas the median overall survival for patients with low Lnc-ATB expression was 51 months (Figure 1d). Moreover, expression of IncRNA correlates with disease-free survival of ESCC patients (\( P = 0.03 \), Figure 1e). Further univariate and multivariate survival analyses showed that TNM stage (\( P < 0.001 \)) and Lnc-ATB expression (\( P = 0.023 \)) were independent prognosis predictors.
indicators of ESCC patients (Table 2). Collectively, Inc-ATB is upregulated in ESCC and predicts poor prognosis of patients.

**Knockdown of Inc-ATB inhibits proliferation and induces cell cycle arrest of ESCC cells.** To explore the functional relevance of dysregulated Inc-ATB in ESCC, KYSE30 and Eca109 cells were selected for further analysis. Isolation of cytoplasmic and nuclear RNAs indicated that Inc-ATB was mainly located in the cytoplasm (Supplementary Figure 1). Lentivirus stably expressing short hairpin RNAs targeting Inc-ATB (sh#1 and sh#2), as well as the scramble sequence (NC) were introduced into ESCC cells and qRT-PCR analysis confirmed effective knockdown of Inc-ATB in KYSE30 and Eca109 cells (Figure 2a). CCK-8 assays revealed that knockdown of Inc-ATB significantly decreased cell viability of ESCC cell lines (KYSE30 and Eca109) (Figure 2b). On the other hand, KYSE30 and Eca109 cells with relative high Inc-ATB expression showed faster proliferation rate than that of KYSE140 and KYSE410 cells with low Inc-ATB expression (Supplementary Figure 2A). Moreover, knockdown of Inc-ATB significantly suppressed formation of colonies compared with sh-control group in KYSE30 and Eca109 cells (Figure 2c). We then investigated whether the anti-proliferation roles of Inc-ATB knockdown was associated with cell cycle arrest or increased apoptosis. To this end, KYSE30 and Eca109 cells (sh#1, sh#2 and negative control (NC)) were subjected to cell cycle and cell apoptosis analysis by flow cytometry. As shown in Figure 2d and Supplementary Figure 2B, knockdown of Inc-ATB significantly induced G2/M phase arrest and apoptosis in KYSE30 and Eca109 cells.

**Knockdown of Inc-ATB inhibits migration and lung metastasis of ESCC cells.** We then sought to investigate migratory and invasive capacity of ESCC cells after knockdown of Inc-ATB. ESCC cells with Inc-ATB reduction had a significant decrease in cell migration (Figure 3a). EMT has vital roles in cancer metastasis.20 Western blot analysis revealed that knockdown of Inc-ATB led to elevated expression of the epithelial markers including E-cadherin and β-catenin and decreased expression of the mesenchymal marker N-cadherin (Figures 3b and c), indicating that EMT may be associated with the pro-metastasis effects of Inc-ATB in ESCC. We then injected Eca109 cells with Inc-ATB suppression into the tail vein of nude mice and found that the metastatic nodules in the lung were significantly decreased in the knockdown group compared with that in the control group (Figures 3d and e).

**Correlation of expression of Lnc-ATB with miR-200b.** Previous studies have reported that many lncRNAs function as a competing endogenous RNAs (ceRNA) to bind disease specific miRNAs such as the case of Inc-ATB and miR-200 family in hepatocellular carcinoma12 and glioma.17 To examine whether Inc-ATB acts in a similar manner, prediction of miRNA target sites in starbase (http://starbase.sysu.edu.cn/) was performed. We found multiple miR-200b-binding sites in Inc-ATB (Figure 4a) and further RNA immunoprecipitation (RIP) analysis confirmed that miR-200b-binding in Figure 2d and Supplementary Figure 2B, knockdown of Inc-ATB significantly induced G2/M phase arrest and apoptosis in KYSE30 and Eca109 cells.

**Knockdown of Inc-ATB inhibits migration and lung metastasis of ESCC cells.** We then sought to investigate migratory and invasive capacity of ESCC cells after knockdown of Inc-ATB. ESCC cells with Inc-ATB reduction had a significant decrease in cell migration (Figure 3a). EMT has vital roles in cancer metastasis.20 Western blot analysis revealed that knockdown of Inc-ATB led to elevated expression of the epithelial markers including E-cadherin and β-catenin and decreased expression of the mesenchymal marker N-cadherin (Figures 3b and c), indicating that EMT may be associated with the pro-metastasis effects of Inc-ATB in ESCC. We then injected Eca109 cells with Inc-ATB suppression into the tail vein of nude mice and found that the metastatic nodules in the lung were significantly decreased in the knockdown group compared with that in the control group (Figures 3d and e).

**Correlation of expression of Lnc-ATB with miR-200b.** Previous studies have reported that many lncRNAs function as a competing endogenous RNAs (ceRNA) to bind disease specific miRNAs such as the case of Inc-ATB and miR-200 family in hepatocellular carcinoma12 and glioma.17 To examine whether Inc-ATB acts in a similar manner, prediction of miRNA target sites in starbase (http://starbase.sysu.edu.cn/) was performed. We found multiple miR-200b-binding sites in Inc-ATB (Figure 4a) and further RNA immunoprecipitation (RIP) analysis confirmed that miR-200b-binding in Figure 2d and Supplementary Figure 2B, knockdown of Inc-ATB significantly induced G2/M phase arrest and apoptosis in KYSE30 and Eca109 cells.

**Table 1** The correlation between clinicopathological parameters and Inc-ATB expression

| Clinicopathological Parameters | Lnc-ATB expression | Age (Low, n (%)) | Age (High, n (%)) | Gender (Male) | Gender (Female) | Alcohol consumption (Never) | Alcohol consumption (Ever) | Smoking status (Never) | Smoking status (Ever) | Tumor size (<5 cm) | Tumor size (≥5 cm) | Differentiation (Poor) | Differentiation (Well or moderate) | TNM stage (I/II) | TNM stage (III) |
|-------------------------------|--------------------|-----------------|-----------------|---------------|----------------|---------------------------|-------------------------|-------------------|-------------------|----------------|----------------|------------------|---------------------|----------------|----------------|
| 44 (58.7) | 31 (41.3) | 44 (58.7) | 31 (41.3) | 44 (58.7) | 31 (41.3) | 63 (84.0) | 12 (16.0) | 59 (78.7) | 16 (21.3) | 41 (54.7) | 34 (45.3) |
| 5 (52.0) | 6 (48.0) | 6 (57.3) | 7 (42.7) | 62 (82.7) | 13 (17.3) | 59 (78.7) | 16 (21.3) | 36 (48.0) | 39 (52.0) |
| 0.511 | 0.550 | 1.000 | 1.000 | 0.514 |

**Table 2** Univariate and multivariate analyses of various potential prognostic factors in ESCC patients

| Prognostic Factors | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|----------------------|
| HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (>60) | 1.22 (0.92–2.24) | 0.112 | — | — |
| Gender (male/female) | 0.92 (0.54–1.56) | 0.757 | — | — |
| Alcohol (never/ever) | 0.98 (0.61–1.58) | 0.921 | — | — |
| Smoke (never/ever) | 0.96 (0.61–1.50) | 0.842 | — | — |
| Tumor size (≥5 cm) | 1.48 (0.84–2.60) | 0.176 | — | — |
| Differentiation (Poor) | 1.49 (0.90–2.47) | 0.118 | — | — |
| TNM stage (I/II) | 3.65 (2.25–5.92) | 0.000 | 3.59 (2.21–5.83) | 0.000 |
| Inc-ATB (high/low) | 1.76 (1.22–2.76) | 0.014 | 1.69 (1.07–2.66) | 0.023 |

Cell Death and Disease
knockdown of lnc-ATB (Figure 4b). Next, we constructed luciferase reporters, which contain wild-type (WT) or mutated (Mut) miR-200b-binding sites, for direct binding validations (Figure 4c). As shown in Figure 4d, miR-200b mimics significantly reduced the luciferase activities of the WT reporter vector but did not affect the activity of the mutant

Figure 2  Knockdown of Lnc-ATB inhibits proliferation and induces cell cycle arrest of ESCC cells. (a) Expression of lnc-ATB was detected in KYSE30 and Eca109 cells after treatment with indicated short hairpin RNAs, whereas sh#1 and sh#2 indicates two independent oligonucleotides targeting lnc-ATB. (b) CCK-8 assays of KYSE30 and Eca109 cells after knockdown of lnc-ATB. (c) Colony formation assays of KYSE30 and Eca109 cells after knockdown of lnc-ATB. (d) Cell cycle assays of KYSE30 and Eca109 cells after knockdown of lnc-ATB. For all quantitative results, the data are presented as the mean ± S.E.M. from three independent experiments. *P<0.05
vector compared with miR-NC, supporting the notion that miR-200b bind bone fide to Inc-ATB. Moreover, miR-200b was significantly upregulated in ESCC cell lines with relative low Inc-ATB expression than cell lines with high expression (Figure 4e). Expression of miR-200b and Inc-ATB showed an inverse correlation pattern in our patient cohort (Figure 4f), providing clues that Inc-ATB may function as ceRNA for miR-200b.

Modulation of Kindlin-2 by Inc-ATB. Decreased expression of miR-200b was reported to predict poor prognosis of ESCC patients and create malignant phenotype via modulation of Kindlin-2.21,22 We found that miR-200b could bind to the 3′-UTR of Kindlin-2 and modulate expression of Kindlin-2 in KYSE30 and Eca109 cells (Figures 5a–c). Moreover, expression of Kindlin-2 was suppressed in KYSE30 and Eca109 cells after knockdown of Inc-ATB (Figure 5d). qRT-PCR analysis indicated that mRNA level of Kindlin-2 was decreased by Inc-ATB knockdown (Figure 5e). Kindlin-2 was previously reported to be involved in the cytoskeleton shaping via RhoA/FAK signaling. Immunoblotting showed that active RhoA and phosphorylated FAK was suppressed after knockdown of Inc-ATB (Figure 5f).

miR-200b/Kindlin-2 mediates oncogenic activity of Inc-ATB. To determine whether miR-200b/Kindlin-2 mediated oncogenic effects of Inc-ATB in ESCC, KYSE30 and Eca109 cells with stable Inc-ATB reduction were transfected with miR-200b inhibitors or a vector with the coding sequence of Kindlin-2 lacking the 3′-UTR (pcDNA-Kindlin-2). We found that miR-200b inhibitors or pcDNA-Kindlin-2 significantly increased mRNA and protein levels of Kindlin-2 (Figures 6a and b). Moreover, attenuation of Kindlin-2 significantly reversed the anti-migration roles of Inc-ATB knockdown (Figure 6c).

Knockdown of Lnc-ATB significantly suppressed tumor growth in vivo. To investigate whether Inc-ATB regulates ESCC tumorigenesis in vivo, Eca109 cells (sh#1, sh#2 and
NC) were subcutaneously injected into the dorsal flank of female nude mice and the tumor volume was monitored. As shown in Figures 7a–c, the volume and weight of xenografts in the knockdown groups were significantly smaller compared with those formed in NC group, which is consistent with in vitro results. Tumor weight was significantly reduced in the knockdown group than that in the control group (Figure 7c). Moreover, qRT-PCR analysis of the dissected xenografts from the knockdown group showed decreased expression of lnc-ATB and increased expression of miR-200b than that from control group (Figures 7d and e). Immunostaining of Ki-67 and Kindlin-2 in dissected tumors showed that silencing of lnc-ATB inhibited proliferation and Kindlin-2 of ESCC cells (Figures 7f–h), indicating that knockdown of lnc-ATB significantly suppressed tumor growth via miR-200b/Kindlin-2 in vivo.

Discussion

ESCC constitutes the main histopathological subtype of esophageal cancer occurring in the central regions of China. The overall prognosis of ESCC remains unsatisfactory despite recent progression in diagnostic methods and therapeutic alternatives. To improve the survival rate of ESCC patients, a better understanding of the genetic and/or epigenetic alterations underlying tumorigenesis and metastasis of ESCC is urgently required. Dysregulation of lncRNAs has been previously reported in a wide range of human cancers including ESCC. For example, the lncRNA MALAT1, HOTTIP, and HOTAIR were overexpressed in ESCC tumor tissues and are good predictive factors for overall survival. Moreover, increased expression of lnc-ATB was observed in breast cancer, gastric cancer, and...
colorectal cancer,\textsuperscript{15,16} indicating that lnc-ATB may function as oncogenes in these cancers. Inspired by these observations, we sought to determine the role of lnc-ATB in ESCC. We were able to detect lnc-ATB in 150 ESCC tumor tissues and paired normal counterparts and draw correlations between the expression of lnc-ATB with clinicopathological parameters. Our data revealed that lnc-ATB was significantly upregulated in ESCC tumor tissues and patients with high lnc-ATB expression showed poorer prognosis than those with low expression. Expression of lnc-ATB was associated with tumor invasion, lymph node metastasis and differentiation state in ESCC. This was validated in our current study, in which elevated lnc-ATB expression was positively correlated with ESCC carcinogenesis. However, Qu \textit{et al.}\textsuperscript{18} reported that expression of lnc-ATB decreased in pancreatic cancer tissues and cell lines, and decreased lnc-ATB expression was an independent predictor of poor prognosis in pancreatic cancer patients. Overall, these data suggest that there is a cancer specific expression pattern of lnc-ATB.

Previous studies have indicated that knockdown of lnc-ATB inhibited EMT and cell invasion in hepatocellular carcinoma\textsuperscript{12} and colorectal cancer\textsuperscript{16} \textit{in vitro} as well as tumor growth in the nude mice. We therefore proceeded to evaluate the biological roles of lnc-ATB in ESCC by short hairpin RNA-mediated loss-of-function assays. Silencing of lnc-ATB expression significantly suppressed proliferation and migration of ESCC cells compared with control. EMT is a critical process associated with tumor progression and metastasis. Our data showed that knockdown of lnc-ATB downregulated Vimentin and N-cadherin and upregulated E-cadherin. These findings demonstrate that lnc-ATB may have a role in EMT.

Tumor-suppressive effects of miR-200 family has been repeatedly verified during the past few years,\textsuperscript{21,22,28,29} whereby miR-200c initiates malignant transformation by modulation of cancer stem cells,\textsuperscript{30} and decreased miR-200 promotes distant metastasis via regulation of the EMT activator ZEB1 and ZEB2.\textsuperscript{31} Moreover, chr1p36 containing...
the miR-200b cluster is often deleted in ESCC.\textsuperscript{32} Over-expression of miR-200b induces cell cycle arrest and represses cell growth, migration and invasion of ESCC cells.\textsuperscript{21,22} Our results showed that expression of miR-200b was significantly upregulated after knockdown of Inc-ATB, and further dual luciferase assays confirmed direct binding of Inc-ATB and miR-200b.

Cells with dynamic assembly of cytoskeleton and active focal adhesion with the surrounding microenvironment are predisposed to local invasion and distant metastasis.\textsuperscript{33} Kindlin-2, a FERM domain containing protein, has been shown to modulate cell migration via interactions with the cytoskeleton, resulting in cell–extracellular matrix adhesions in human cancers including ESCC.\textsuperscript{21,22,34–37} Furthermore,
overexpression of Kindlin-2 was observed in the invasive front of malignant mesothelioma and breast cancer, whereas knockdown of Kindlin-2 exerts tumor-suppressive roles. Upregulation of Kindlin-2 induced by decreased miR-200b promotes malignant phenotype of ESCC and predicts unfavorable prognosis. In this study, we found that overexpression of lnc-ATB may function as molecular sponge of Kindlin-2 and miR-200b. Attenuation of the anti-proliferative roles of lnc-ATB knockdown by re-induction of Kindlin-2 in ESCC cells further demonstrated the role of the lnc-ATB/miR-200b/Kindlin-2 axis in tumor metastasis. Notably, this mechanism may correlate with our clinical observations that the loss of miR-200b in ESCC tumors is associated with lymph node metastasis, advanced clinical stage and short survival.

**Conclusions**

Our current study demonstrates that upregulation of lnc-ATB is associated with ESCC progression. Our results provide new insights into the dysregulated lnc-ATB/miR-200b/Kindlin-2 axis in the development of ESCC and suggest that lnc-ATB represent a potential therapeutic target for ESCC.

**Materials and Methods**

**Patients and samples.** The ESCC tumor tissues and corresponding normal esophageal epithelial tissues were obtained from 150 patients who underwent surgery at the Sun Yat-sen University Cancer Center from 2007 to 2009, Guangzhou, China. No patients enrolled in our study were given local or systemic treatment before surgery. Clinicopathological data were collected from medical records. All specimens were snap-frozen immediately after resection from the patient and stored at −80 °C until RNA extraction.
**Cell lines and cell culture.** The human ESCC cell lines (KYE150, KYSE140, KYSE410, KYSE520, KYSE510, Ec109, Ec9706 and KYSE30) were obtained either from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) or purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). The human embryonic kidney cell line HEK293a were purchased from the American Type Culture Collection (Manassas, VA, USA). All cells were cultured in Dulbecco’s modified essential medium supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA), 100 U/ml penicillin (Sigma-Aldrich, St. Louis, MO, USA) and 100 μg/ml streptomycin (Sigma-Aldrich) and maintained in a humidified incubator at 37 °C with 5% CO₂.

**RNA extraction and quantitative real-time PCR.** Total RNAs from cell lines and tissue samples was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Cytoplasmic and nuclear RNA were isolated with the commercial kit (NORGEN, Thorold, ON, Canada) according to the manufacturer’s instructions. RNA concentration and quality were evaluated by the 260/280 nm absorbance with a Nanodrop Spectrophotometer (IMPLEN GmbH, Munich, Germany). The RNA was then reversely transcribed to cDNA with the PrimeScript RT Master Mix (Takara Biotechnology, Dalian, China). SYBR Green Mix (Promega, Madison, WI, USA) was used to detect expression of lnc-A TB and Kindlin-2, whereas GAPDH was used as an internal control. The primer sequences were as follows:

- **Inc-ATB forward:** 5′-CTGGCAGGCTGCTGGAC-3′
- **Inc-ATB reverse:** 5′-ATCCGTTGCTGGTAAAGG-3′
- **Kindlin-2 forward:** 5′-TGTCTCCCCGTACCTAAAAGGT-3′
- **Kindlin-2 reverse:** 5′-TGTCTCCCCGTACCTAAAAGGT-3′
- **E-Cadherin forward:** 5′-GGAGGCTAGACAAAGGAAATG-3′
- **E-Cadherin reverse:** 5′-GGTGTGAGGGGAAATGAGG-3′
- **GAPDH forward:** 5′-GCAAAGCACAAGGAAGAAGA-3′
- **GAPDH reverse:** 5′-ACTGTGAGGAGGGAGATTC-3′.

For measurement of miRNAs, TaqMan MicroRNA Assay kits (Applied Biosystems, Darmstadt, Germany) were used and real-time PCR reaction was carried out using ABI 7500 fast real-time PCR system (Applied Biosystems). U6 served as the internal control. PCR cycling conditions were 10 min at 95 °C followed by 45 cycles of 95 °C for 15 s and 60 °C for 60 s. All reactions were performed in triplicates. The fold change for each gene relative to the control group was calculated using the 2^ΔΔCt method.

**Cell transfection.** Lentivirus containing the short hairpin RNA targeting human Inc-ATB (Supplementary Table 2) was obtained from GenePharma (Shanghai, China), and was labeled as sh1, sh2 and its corresponding non-targeting sequence (shNC). The ESCC cells were transfected with the lentivirus before they were selected with puromycin (3 μg/ml) for 72 h and the efficiency was confirmed by GFP-positive cells percentage. The miR-200b mimics, miR-200b inhibitors and miR-200b NC were synthesized by GenePharma. Eca109 cells with Inc-ATB reduction were injected into the tail vein of nude mice (n = 6 per group). Eight weeks post injection, the mice were killed and the lungs were removed and paraffin embedded. Consecutive sections (4 μm) were made and stained with hematoxylin-eosin. The microvessels were counted and analyzed.
LncRNA ATB predicts poor prognosis in esophageal carcinoma
Z Li et al

Statistical analysis. All statistical analyses were performed using the SPSS 19.0 statistical software package (SPSS, Chicago, IL, USA). The data are representative of three independent experiments and are presented as mean value ± S.D. To evaluate significant differences between two independent groups of samples, Student’s t test was used. The Kaplan–Meier method was used to generate the survival curve and compared using the log-rank test. The chi-square test or Fisher’s exact test was used to analyze the association of Inc-ATB expression with clinicopathological parameters. P value < 0.05 was considered to be statistically significant.

Conflict of Interest
The authors declare no conflict of interest.

Acknowledgements. This work was supported by grants from Guizhou Province Science and Technology Cooperation (no. LH(2015)7486) and Guizhou Provincial People’s Hospital Youth Funding (no. GZSQN(2016)20).

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
2. Adens A, Robb WB, Maritote C. Esophageal carcinoma. N Engl J Med 2015; 372: 1471.
3. Chen W, Zheng R, Baade PD, Zeng H, Bray F et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–125.
4. Rustgi A, El-Serag HB. Esophageal carcinoma. N Engl J Med 2015; 372: 1472–1473.
5. Wu CC, Chen CJ. Esophageal carcinoma. N Engl J Med 2015; 372: 1472.
6. Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 1991; 48: 411–420.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674.
8. Good MC, Zalatan JG, Lim WA. Scaffold proteins: hubs for controlling the flow of cellular information. Science 2011; 332: 680–686.
9. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell 2013; 152: 1298–1307.
10. Ulltisky I, Barait DP. IncRNAs: genomics, evolution, and mechanisms. Cell 2013; 154: 26–46.
11. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629–641.
12. Yuan JH, Yang F, Wang F, Ma JZ, Guo YY, Tao QF et al. A long non coding RNA activated by TGF-beta promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 2014; 25: 666–681.
13. Shi SJ, Wang LJ, Yu B, Li YH, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget 2015; 6: 11652–11663.
14. Saito T, Kurashige J, Nambara S, Komatsu H, Hirata H, Ueda M et al. A long non-coding RNA activated by transforming growth factor-beta is an independent prognostic marker of gastric cancer. Ann Surg Oncol 2015; 22(Suppl 3): S915–S922.
15. Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H et al. LncRNA-ATB is involved in the progression and prognosis of colorectal cancer. Anticancer Res 2015; 35: 1385–1388.
16. Yue B, Qiu S, Zhao S, Liu C, Zhang D, Yu F et al. LncRNA-ATB mediated E-cadherin repression promotes the progression of colon cancer and predicts poor prognosis. J Gastroenterol Hepatol 2016; 31: 595–603.
17. Ma CC, Xiong Z, Zhu GN, Wang C, Zong G, Wang HL et al. Long non-coding RNA ATB promotes glioma malignancy by negatively regulating miR-200a. J Exp Clin Cancer Res 2016; 35: 90.
18. Ou S, Yang X, Song W, Sun W, Li X, Wang J et al. Downregulation of IncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic carcinoma. Tumour Biol 2016; 37: 3933–3938.
19. Xiong J, Liu Y, Jiang L, Zeng Y, Tang W. High expression of long non-coding RNA IncRNA-ATB is correlated with metastases and promotes cell migration and invasion in renal cell carcinoma. Jpn J Clin Oncol 2016; 46: 378–384.
20. Nieto MA, Huang RY, Jackson RA, Thery JP. Emt. Cell 2016; 166: 21–45.
21. Zhang HF, Alishaaref A, Wu C, Jiao JW, Sorensen PH, Bai XZ et al. miR-200b induces cell cycle arrest and represses cell growth in esophageal squamous cell carcinoma. Carcinogenesis 2016; 37: 858–869.
22. Zhang HF, Zhang K, Liao LD, Li Y, Wu BL et al. miR-200b suppresses invasiveness and modulates the cytoskeletal and adhesive machinery in esophageal squamous cell carcinoma cells via targeting Kindlin-2. Carcinogenesis 2014; 35: 232–239.
23. Hu L, Wu Y, Tan D, Meng H, Wang K, Bai Y et al. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2015; 34: 7.
24. Ding J, Lu B, Wang J, Wang S, Shi Y, Liu Y et al. Long non-coding RNA Lnc542d2 induces apoptosis in colorectal cancer cells via the caspase cleavage cascades. J Exp Clin Cancer Res 2015; 34: 100.
25. Wang W, Zhu Y, Li S, Chen X, Jiang G, Shen Z et al. Long noncoding RNA MALAT1 promotes malignant development of esophageal squamous cell carcinoma by targeting beta-catenin via Ezh2. Oncotarget 2016; 7: 25668–25682.
26. Chen X, Han H, Li Y, Zhang Q, Mo K, Chen S. Upregulation of long noncoding RNA HOTTIP promotes metastasis of esophageal squamous cell carcinoma via induction of EMT. Oncotarget 2016; 7: 84485–84485.
27. Ren K, Li Y, Lu H, Liu Z, Wu K et al. Long non-coding RNA HOTAIR controls cell cycle by functioning as a competing endogenous RNA in esophageal squamous cell carcinoma. Transl Oncol 2016; 9: 489–497.
28. Yu Y, Wu J, Guan LQ, Li H, Yang M, et al. Kindlin-2 promotes breast cancer invasion via epigenetic silencing of the microRNA200 gene family. Int J Cancer 2013; 133: 1368–1379.
29. Feng X, Wang Z, Filimore R, Xi Y. MiR-200, a new star miRNA in human cancer. Cancer Lett 2014; 344: 166–173.
30. Banerjee P, Dutta S, Pal R. Dysregulation of Wnt-signaling and a candidate set of miRNAs underlie the effect of metformin on neural crest cell development. Stem Cells Dev 2016; 34: 334–345.
31. Perdigas-Henriques R, Petrocca F, Altschuler G, Thomas MP, LeMT, Tan SM et al. MiR-200B regulates the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes. Oncogene 2016; 35: 158–172.
32. Qin YR, Wang LD, Fan ZM, Kwong D, Guan XY. Comparative genomic hybridization analysis of genetic aberrations associated with development of esophageal squamous cell carcinoma in Henan, China. World J Gastroenterol 2008; 14: 1628–1635.
33. Lu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell 2016; 30: 688–681.
34. Ren Y, JI H, Xue Z, Xu Q, Wang S, Zhao G et al. Kindlin-2 inhibited the growth and migration of colorectal cancer cells. Tumour Biol 2015; 36: 4107–4114.
35. Guo B, Gao J, Zhan J, Zhan H, Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced breast cancer cell migration. Cancer Lett 2015; 361: 271–281.
36. Ren C, Du J, XIC, Yu Y, Hu A, Zhan J et al. Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes. Biochem Biophys Res Commun 2014; 446: 187–194.
37. Fang JR, Pan TJ, Yang H, Wang T, Liu W, Liu B et al. Kindlin-2 promotes invasiveness of prostate cancer cells via NF-kappaB-dependent upregulation of matrix metalloproteinases. Gene 2016; 576(1 Pt 3): 571–576.
38. An Z, Dobra K, Lock JG, Stromblad S, Hjerpe A, Zhang H. Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration. Int J Cancer 2010; 127: 1999–2008.

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/